BIOAGE Labs Inc

BIOA remains in a Stage 2 advancing trend after the mid-June breakout. Recent bearish exhaustion and a pullback below the 9/21 EMAs show short-term weakness, but the higher-high/higher-low sequence and rising 50 DMA remain intact. Medium-term bias stays bullish, while timing favors staging entries on pullbacks into the 50 DMA and mid-June pivot support area.

• ↑Phase 2 dosing of BGE-102 represents pivotal pipeline advancement.
• ↑Phase 1 results showed significant CRP reduction, validating efficacy.
• ↓Negative earnings yield and elevated leverage risk stress financial stability.